<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04860050</url>
  </required_header>
  <id_info>
    <org_study_id>AFCRO-125</org_study_id>
    <nct_id>NCT04860050</nct_id>
  </id_info>
  <brief_title>Turmeric for Memory Impairment and Cognition</brief_title>
  <acronym>TURMEMIC</acronym>
  <official_title>A Double Blind, Parallel, Placebo-controlled, Randomised Clinical Trial to Evaluate the Efficacy of Turmipure Gold® to Improve Cognitive Performance in Healthy Aging.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Naturex SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Atlantia Food Clinical Trials</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Naturex SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to test the capacity of acute and chronic supplementations of&#xD;
      Turmipure GOLD® to improve cognitive performance in healthy aging&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this clinical study is to determine whether oral administration of Turmipure GOLD®&#xD;
      can contribute to the short- and long-term improvement of cognitive functions, including&#xD;
      memory and attention, in subjects with age-associated memory impairment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cognitive performance through Quality of Working memory</measure>
    <time_frame>24 weeks</time_frame>
    <description>Quality of Working memory is a composite score determined by the CDR System™ test battery (unit: #)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive performance through Power of Attention</measure>
    <time_frame>24 weeks</time_frame>
    <description>Power of Attention is a composite score determined by the CDR System™ test battery (unit: ms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive performance through Continuity of Attention</measure>
    <time_frame>24 weeks</time_frame>
    <description>Continuity of Attention is a composite score determined by the CDR System™ test battery (unit: #)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive performance through Cognitive Reaction Time</measure>
    <time_frame>24 weeks</time_frame>
    <description>Cognitive Reaction Time is a composite score determined by the CDR System™ test battery (unit: ms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive performance through Speed of Memory</measure>
    <time_frame>24 weeks</time_frame>
    <description>Speed of Memory is a composite score determined by the CDR System™ test battery (unit: ms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive performance through Quality of Episodic Memory</measure>
    <time_frame>24 weeks</time_frame>
    <description>Quality of Episodic Memory is a composite score determined by the CDR System™ test battery (unit: #)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive performance through Quality of Memory</measure>
    <time_frame>24 weeks</time_frame>
    <description>Quality of Memory is a composite score determined by the CDR System™ test battery (unit: #)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive performance through Executive Function</measure>
    <time_frame>24 weeks</time_frame>
    <description>Executive Function is a composite score determined by the CDR System™ test battery (unit: #)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in stress</measure>
    <time_frame>24 weeks</time_frame>
    <description>Stress will be assessed using the validated scale Perceived Stress Scale (0 to 56, higher scores meaning at maximum stress)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in feelings and emotions</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mood will be assessed using the validated Positive and Negative Affect Schedule - Expanded Form (PANAS-X) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mood</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mood will be assessed using the validated Bond-Lader questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Cognitive Change</condition>
  <condition>Mood</condition>
  <condition>Stress</condition>
  <arm_group>
    <arm_group_label>TPG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>76 participants who meet the eligibility criteria will be randomized under experimental arm and will receive Turmipure GOLD® product during 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>76 participants who meet the eligibility criteria will be randomized under experimental arm and will receive placebo (colored acacia gum) product during 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Turmipure Gold®</intervention_name>
    <description>TPG: Turmipure GOLD® - 1 capsule per day - as prescribed</description>
    <arm_group_label>TPG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: colored acacia gum - 1 capsule per day - as prescribed</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consent to the study and willing/able to comply with study product&#xD;
&#xD;
          -  Males and females aged ≥ 60 and ≤ 85 years old&#xD;
&#xD;
          -  Participants with subjective memory impairment, with preserved global cognitive&#xD;
             functions, everyday activities, and no dementia, fulfilling age-associated memory&#xD;
             impairment criteria based on the following National Institute of Mental Health&#xD;
             criteria (AAMI, Crook 1986):&#xD;
&#xD;
               1. Subjective memory complaint reflected in everyday difficulties (gradual)&#xD;
                  confirmed with a MAC-Q ≥25&#xD;
&#xD;
               2. Memory loss confirmed by a 1st degree relative or life-partner&#xD;
&#xD;
               3. Memory test performance that is at least 1SD below the mean established for&#xD;
                  healthy adults on a standardised test of secondary memory (VPA I and II portions&#xD;
                  of the Wechsler Memory Scale IV)&#xD;
&#xD;
               4. Evidence of adequate intellectual function as determined by the Vocabulary subset&#xD;
                  of the Wechsler Adult Intelligence Scale&#xD;
&#xD;
               5. Absence of dementia, as determined by the Telephone - Mini-Mental State&#xD;
                  Examination (MMSE) predicted in person score ≥24&#xD;
&#xD;
          -  Not suffering from depression or anxiety, as determined by the Hospital Anxiety and&#xD;
             Depression Scale (HADs) score of ≤7 for both depression and anxiety&#xD;
&#xD;
          -  With a BMI between 18 and 32 kg/m²&#xD;
&#xD;
          -  With a glycated haemoglobin/A1C score ≤ 5.7 %&#xD;
&#xD;
          -  Willing to maintain existing dietary, body weight, and physical activity patterns&#xD;
             throughout the study period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal laboratory test results of clinical significance&#xD;
&#xD;
          -  With significant cardiovascular history, or significant cardiovascular, pulmonary,&#xD;
             renal, liver, infectious disease, immune disorder, or metabolic/endocrine disorders or&#xD;
             other disease that would preclude supplement ingestion and/or assessment of safety and&#xD;
             the study objectives, as deemed exclusionary by the Principal Investigator&#xD;
&#xD;
          -  With history of major head trauma, chronic traumatic encephalopathy, epilepsy,&#xD;
             cerebrovascular disease, stroke or clinically diagnosed with mild cognitive impairment&#xD;
             or dementia (such as Alzheimer's Disease according to the NINCDS-ADRDA guidelines),&#xD;
             acute psychiatric disorder, schizophrenia, mania, depression (within past 24 months)&#xD;
             or under any concurrent medical, cognitive or psychiatric condition that would either:&#xD;
             compromise his/her ability to comply with the study requirements, may pose significant&#xD;
             risk to the subject, or be deemed exclusionary by the Principal Investigator&#xD;
&#xD;
          -  History of heavy smoking (&gt; 1 pack/day) within past 3 months&#xD;
&#xD;
          -  History of heavy caffeinated beverage consumption (&gt; 400 mg caffeine/day) within past&#xD;
             2 weeks&#xD;
&#xD;
          -  Taking any supplements or vitamins notably known to affect cognitive function (e.g.&#xD;
             Living Nutrition Cognitive, Viridian Cognitive Complex, fish oil etc., list not&#xD;
             exhaustive), or any psychotropic medications and products which interact with&#xD;
             acetylcholine esterase and/or NMDA receptors (6-week washout before screening).&#xD;
             Vitamin D and Calcium supplements permitted if on a stable dose for the previous 3&#xD;
             months&#xD;
&#xD;
          -  Participant with history of drug and/or alcohol abuse at the time of enrolment&#xD;
&#xD;
          -  Significant change of dietary habits within the preceding month&#xD;
&#xD;
          -  With known organic disease, including an inflammatory bowel disease, a benign or&#xD;
             malign tumour of intestine or colon or significant systemic disease, and with history&#xD;
             of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin&#xD;
             carcinoma, prostate cancer or carcinoma in situ with no significant progression over&#xD;
             the past 2 years&#xD;
&#xD;
          -  Participant with known allergy to components of the test product or with a medical&#xD;
             history of food allergies&#xD;
&#xD;
          -  Having uncontrolled hypertension, uncontrolled hypothyroidism or hyperthyroidism or&#xD;
             uncontrolled lipidaemia (hypercholesteremia or hypertriglyceridemia) that is not on&#xD;
             stable medication for at least 3 months.&#xD;
&#xD;
          -  Current illnesses which could interfere with the study (e.g. prolonged severe&#xD;
             diarrhoea, regurgitation/severe, difficulty swallowing)&#xD;
&#xD;
          -  Participants taking any anticoagulant (including aspirin) or heparin treatment&#xD;
&#xD;
          -  Participant currently involved in any other clinical trial or having participated in a&#xD;
             trial within the preceding 90 days&#xD;
&#xD;
          -  Individuals who are unable to give informed consent&#xD;
&#xD;
          -  Participant has a history of non-compliance with medical treatments or recommendations&#xD;
&#xD;
          -  Occupations that resulted in disruption of sleep-wake cycles&#xD;
&#xD;
          -  Participant has difficulty hearing with or without a hearing aid or is colour blind or&#xD;
             is visually impaired&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Dinan, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atlantia Clinical Food Trials</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie Laval, PhD</last_name>
    <phone>+33 4 90 23 70 76</phone>
    <email>julie.laval@givaudan.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pascale Fança-Berthon, PhD</last_name>
    <phone>+33 4 90 23 28 40</phone>
    <email>pascale.fanca-berthon@givaudan.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Atlantia Food Clinical Trials</name>
      <address>
        <city>Cork</city>
        <zip>T23 R50R</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Goodbody</last_name>
      <phone>+353(0)214307442</phone>
      <email>egoodbody@atlantiafoodtrials.com</email>
    </contact>
    <contact_backup>
      <last_name>Aisling Harrington</last_name>
      <phone>+353(0)214307442</phone>
      <email>aharrington@atlantiatrials.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Turmeric</keyword>
  <keyword>Curcuminoids</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

